Motif Bio’s (MTFB) “Under Review” Rating Reiterated at Peel Hunt

Peel Hunt reiterated their under review rating on shares of Motif Bio (LON:MTFB) in a research report report published on Thursday, ThisIsMoney.Co.Uk reports.

MTFB stock opened at GBX 2.64 ($0.03) on Thursday. Motif Bio has a 1 year low of GBX 2 ($0.03) and a 1 year high of GBX 44.90 ($0.59). The company has a fifty day moving average of GBX 2.63. The company has a market capitalization of $9.05 million and a PE ratio of -0.37.

About Motif Bio

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Further Reading: What is quantitative easing?

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.